Datroway
What Datroway is used for
Breast cancer Datroway as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Datroway
- Active substance
- datopotamab deruxtecan
- Disease area
- Breast Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX35
- Marketing authorisation holder
- Daiichi Sankyo Europe GmbH
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Datroway
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Datroway used for?
Breast cancer Datroway as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.
What is the active substance in Datroway?
Datroway contains datopotamab deruxtecan.
Who makes Datroway?
The EU marketing authorisation holder is Daiichi Sankyo Europe GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU